Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q1 2024 Earnings Presentation

41 slides from Neurocrine Biosciences's earnings presentation, May 1, 2024

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q1 2024 Corporate Presentation May 1, 2024 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well-Positioned for Sustained & Long-term Growth

    Well-Positioned for Sustained & Long-term Growth Commercial R&D Focus Strong Financial Position * Neurology ~$1.9B TARDIVE DYSKINESIA AND CHOREA Neuroendocrinology Cash and Investments ASSOCIATED WITH HUNTINGTON’S DISEASE as of 3/31/2024 Neuropsychiatry $2.1 - $2.2 2024 Annual Net Sales Guidance Bil

  4. Slide 4: Where Are We Today?

    Where Are We Today? • Discovered and Developed Three Novel FDA-Approved Programs • Deep Expertise in Neuroscience Drug Development • Fully-Integrated Organization with Both R&D and Commercial Capabilities • Growing Blockbuster Commercial Product in INGREZZA with Strong IP Protection • Future Blockbu

  5. Slide 5: Q1 2024 Highlights and 2024 Key Milestones and Activities

    Q1 2024 Highlights and 2024 Key Milestones and Activities Q1 2024 / Recent Highlights 2024 Key Milestones and Activities ▪ Positive Phase 2 Top-Line Data For NBI-’845 (AMPA Potentiator) ▪ Settle Senior Convertible Notes Due in May in Cash in Adults with Major Depressive Disorder (MDD) ▪ Present Effi

  6. Slide 6: Building and Maximizing the Pipeline

    # of Programs by Stage Building and Maximizing the Pipeline Phase 1 5 Phase 2 8 Phase 3 2 NDA 2 Phase 1 Phase 2 Phase 3 NDA Milestone Neurology valbenazine* Dyskinetic Cerebral Palsy VMAT2 Inhibitor Phase 3 Ongoing NBI-8271042 EE-CSWS Cav 3.1, 3.2, 3.3 Phase 2 Ongoing NBI-9213523 SCN8A-DEE Nav1.6 Ph

  7. Slide 7: Q1 2024 Financial Summary

    Q1 2024 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q1 2024 Q1 2023 Highlights / Comments Revenue $515 $420 INGREZZA Sales of $506M Represents YoY Growth - Product Sales, Net 509 415 of 23% Driven by Strong Underlying Patient Demand and Improvement in Gross-to-Net Dynamics

  8. Slide 8: Reaffirmed 2024 INGREZZA Net Sales Guidance and Updated Expense Guidance

    Reaffirmed 2024 INGREZZA Net Sales Guidance and Updated Expense Guidance 2023 2024 Previous 2024 Current Item ($ Millions) Comments Actuals Guidance Range Guidance Range Net Sales INGREZZA Net Product Sales1 $1,836 $2,100 - $2,200 $2,100 - $2,200 Guidance Reaffirmed GAAP R&D Expense2 $565 $645 - $67

  9. Slide 9: Corporate Sustainability: A Rated at MSCI

    Corporate Sustainability: “A” Rated at MSCI and Rank in 11th Percentile for Biotech at Sustainalytics Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safe

  10. Slide 10: Our Medicines, Our Patients

    © NEYROCRINE Our Medicines, Our Patients

  11. Slide 11: Multiple Commercial Products

    Multiple Commercial Products In the U.S. In the U.S. and Europe † * ENDOMETRIOSIS ADRENAL INSUFFICIENCY In Europe TARDIVE DYSKINESIA † CHOREA ASSOCIATED WITH HD UTERINE FIBROIDS CONGENITAL ADRENAL HYPERPLASIA HD = Huntington’s Disease *Mitsubishi Tanabe Pharma Corporation (MTPC) has commercializatio

  12. Slide 12: INGREZZA

    INGREZZA (valbenazine) capsules NEUROCRINE BIOSCIENCES

  13. Slide 13: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) Q1 2024 Sales of $506M Represents $550 23% Year-Over-Year Growth vs. Q1 2023 $506 $500 $500 $486 $450 $440 $410 $399 $400 $376 $350 $350 $300 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 13

  14. Slide 14: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  15. Slide 15: Nascent Tardive Dyskinesia Market Presents Significant Opportunity

    Nascent Tardive Dyskinesia Market Presents Significant Opportunity Approximately 35% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment with a VMAT2 inhibitor like INGREZZA people in the U.S. ~35% ~18% TD Increasing Antipsychotic Pr

  16. Slide 16: INGREZZA Approved by the FDA for Chorea Associated with Huntington's Disease

    INGREZZA® Approved by the FDA for the Treatment of Chorea Associated with Huntington’s Disease INGREZZA Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In randomized, double-blind

  17. Slide 17: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA INGREZZA® SPRINKLE (valbenazine) oral granules formulation approved 4/30/24 IP Protection to 2038 Additional indication to treat chorea associated with Huntington’s disease Salesforce and distribution expansion Investing in telemedicine capabilities Recommends p

  18. Slide 18: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  19. Slide 19: NBI-1065845 (AMPA Potentiator): Positive Phase 2 Top-Line Results in MDD

    NBI-1065845* (AMPA Potentiator): Reported Positive Phase 2 Top- Line Study Results in Adults with Major Depressive Disorder Inadequate Response to Treatment NBI-1065845 (or NBI-’845) in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Ora

  20. Slide 20: NBI-1065845: SAVITRI Phase 2 Study Summary Results

    NBI-1065845* (AMPA Potentiator): SAVITRITM Phase 2 Study Summary Results EFFICACY SAFETY AND TOLERABILITY • The study met its primary and key secondary endpoints • NBI-1065845 was generally well-tolerated • Once-daily, oral administration of NBI-’845 produced a • Most common adverse event was headac

  21. Slide 21: Luvadaxistat: DAAO Inhibitor in Phase 2 Study

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor in Phase 2 Study with Top-Line Data Expected in Q3 2024 Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagno

  22. Slide 22: Developing Novel Muscarinic System Portfolio

    Developing Novel Muscarinic System Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio ➢ Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia with top-line data expected in Q3 2024 ✓ NBI-1117568 offers the potential for an i

  23. Slide 23: Valbenazine: ATS Study Will Inform Next-Generation VMAT2 Inhibitors

    Valbenazine*: ATS Study Will Inform Development of Our Next-Generation VMAT2 Inhibitors Including NBI-1065890 (Currently in Phase 1) Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A seriou

  24. Slide 24: Neuroendocrinology Pipeline

    Neuroendocrinology Pipeline

  25. Slide 25: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue

  26. Slide 26: Classic CAH Due to 21-Hydroxylase Deficiency (21OHD CAH)

    Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH) High ACTH and Androgen Excess TARTs Cortisol Excess From Supraphysiologic GC Dosing Hirsutism, Infertility amenorrhea Psychological 21OHD CAH Results in: Diabetes, Abnormal and/or early effects insulin resistance Sho

  27. Slide 27: Classic CAH Due to 21-Hydroxylase Deficiency (21OHD CAH)

    Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH) Cortisol Excess From Supraphysiologic GC Dosing Obesity Cardiovascular striae Diabetes, Psychological High ACTH and Androgen Excess insulin resistance 21OHD CAH Results in: risk Short stature Fractures, effects Hirsu

  28. Slide 28: Classic CAH Due to 21-Hydroxylase Deficiency (21OHD CAH)

    Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH) 21OHD CAH Results in: Reduced GC Dosing crinecerfont Androgen Control • Impaired Synthesis of Cortisol and (Often) Aldosterone • Excess Adrenal Androgen Production Treatment Must Balance Consequences of: • Supraphysi

  29. Slide 29: CAHtalyst Adult and Pediatric Study Androgen Reduction

    CAHtalystTM Adult and Pediatric Study Androgen Reduction Percent Change* in Androstenedione at Week 4 (Following Glucocorticoid Stable Period) Adult Study Pediatric Study Study Characteristic Key Takeaways (N = 182) (N = 103) Substantial and Meaningful Reduction in Patients Receiving Crinecerfont -4

  30. Slide 30: CAHtalyst Glucocorticoid Dose Reduction While Maintaining Androgen Control

    CAHtalystTM Adult and Pediatric Study Glucocorticoid Dose Reduction While Maintaining Androgen Control Percent of Subjects Achieving a Glucocorticoid Daily Dose ≤ 11 mg/m2/day While Maintaining Androgen Control Adult Study @ Pediatric Study @ CAHtalystTM Trial Participants Key Takeaways Week 24 Week

  31. Slide 31: CAHtalyst Adult and Pediatric Study Safety and Tolerability

    CAHtalystTM Adult and Pediatric Study Safety and Tolerability • Crinecerfont Treatment was Overall Well-Tolerated with Few Serious Adverse Events (SAEs), None Were Assessed as Related to Crinecerfont • Most Common Adverse Events During the Double-Blind, Placebo-Controlled Period of the Adult Study w

  32. Slide 32: Crinecerfont Program Next Steps

    Crinecerfont Program Next Steps • New Drug Applications (NDAs) Have Been Submitted to the FDA and Will Be Submitted Later to the European Medicines Agency • Additional Information Regarding Results from the CAHtalystTM Pediatric and Adult Studies Will Be Provided at a Number of Medical Conferences i

  33. Slide 33: Neurology Pipeline

    © NEVROCRINE Neurology Pipeline

  34. Slide 34: Valbenazine: Registrational Program in Dyskinetic Cerebral Palsy

    Valbenazine*: Registrational Program in Dyskinetic Cerebral Palsy Dyskinetic Cerebral Palsy (DCP) A form of cerebral palsy (CP) that affects ~15% of the approximately 500,000 to 1M people in the U.S. diagnosed with the disease. Can result in a range of developmental delays, physical difficulties and

  35. Slide 35: Well-Positioned for Sustained & Long-term Growth

    Well-Positioned for Sustained & Long-term Growth Commercial R&D Focus Strong Financial Position * Neurology ~$1.9B TARDIVE DYSKINESIA AND CHOREA Neuroendocrinology Cash and Investments ASSOCIATED WITH HUNTINGTON’S DISEASE as of 3/31/2024 Neuropsychiatry $2.1 - $2.2 2024 Annual Net Sales Guidance Bil

  36. Slide 36: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  37. Slide 37: Condensed Consolidated Statements of Operations

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) Revenues: Net product sales Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and dev

  38. Slide 38: Condensed Consolidated Balance Sheets

    NEUROCRINE OSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS $ $ $ (unaudited) March 31, (in millions) 2024 Cash, cash equivalents and marketable securities $ 1,210.6 Other current assets 588.4 Total current assets 7799.0 Deferred tax assets 378.2 Debt securities available

  39. Slide 39: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended March 31, (in millions, except per share data) 2024 2023 GAAP net income (loss) $ 44 $ (76.6) Adjustments: Stock-based compensation expense - R&D 17.0 13.8 Stock-based compensation expens

  40. Slide 40: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) ‘Three Months Ended (in millions) GAAP cost of revenues $ Adjustments: ‘Non-cash amortization related to acquired intangible assets 09 09 Non-GAAP cost of revenues 5 66 $ 76 Three Months Ended March 31, (in millions

  41. Slide 41: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q1 2024 Corporate Presentation May 1, 2024 Nasdaq: NBIX

Neurocrine Biosciences — Q1 2024 Earnings Presentation on 6ix